Cargando…
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of diabetes management despite recent scepticism about tight glucose control strategies. The impact on...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814090/ https://www.ncbi.nlm.nih.gov/pubmed/20456169 http://dx.doi.org/10.1111/j.1742-1241.2009.02227.x |
_version_ | 1782176973155467264 |
---|---|
author | Prato, S Del LaSalle, J Matthaei, S Bailey, C J |
author_facet | Prato, S Del LaSalle, J Matthaei, S Bailey, C J |
author_sort | Prato, S Del |
collection | PubMed |
description | Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of diabetes management despite recent scepticism about tight glucose control strategies. The impact on macrovascular complications is still a matter of debate, and so glycaemic control strategies should be placed in the context of multifactorial intervention to address all cardiovascular risk factors. Approaches to achieve glycaemic targets should always ensure patient safety, and results from recent landmark outcome studies support the need for appropriate individualisation of glycaemic targets and of the means to achieve these targets, with the ultimate aim to optimise outcomes and minimise adverse events, such as hypoglycaemia and marked weight gain. The primary goal of the Global Partnership for Effective Diabetes Management is the provision of practical guidance to improve patient outcomes and, in this article, we aim to support healthcare professionals in appropriately tailoring type 2 diabetes treatment to the individual. Patient groups requiring special consideration are identified, including newly diagnosed individuals with type 2 diabetes but no complications, individuals with a history of inadequate glycaemic control, those with a history of cardiovascular disease, children and individuals at risk of hypoglycaemia. Practical guidance specific to each group is provided. |
format | Text |
id | pubmed-2814090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-28140902010-02-12 Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management Prato, S Del LaSalle, J Matthaei, S Bailey, C J Int J Clin Pract Consensus Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of diabetes management despite recent scepticism about tight glucose control strategies. The impact on macrovascular complications is still a matter of debate, and so glycaemic control strategies should be placed in the context of multifactorial intervention to address all cardiovascular risk factors. Approaches to achieve glycaemic targets should always ensure patient safety, and results from recent landmark outcome studies support the need for appropriate individualisation of glycaemic targets and of the means to achieve these targets, with the ultimate aim to optimise outcomes and minimise adverse events, such as hypoglycaemia and marked weight gain. The primary goal of the Global Partnership for Effective Diabetes Management is the provision of practical guidance to improve patient outcomes and, in this article, we aim to support healthcare professionals in appropriately tailoring type 2 diabetes treatment to the individual. Patient groups requiring special consideration are identified, including newly diagnosed individuals with type 2 diabetes but no complications, individuals with a history of inadequate glycaemic control, those with a history of cardiovascular disease, children and individuals at risk of hypoglycaemia. Practical guidance specific to each group is provided. Blackwell Publishing Ltd 2010-02 /pmc/articles/PMC2814090/ /pubmed/20456169 http://dx.doi.org/10.1111/j.1742-1241.2009.02227.x Text en © 2010 Blackwell Publishing Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Consensus Prato, S Del LaSalle, J Matthaei, S Bailey, C J Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
title | Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
title_full | Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
title_fullStr | Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
title_full_unstemmed | Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
title_short | Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
title_sort | tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management |
topic | Consensus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814090/ https://www.ncbi.nlm.nih.gov/pubmed/20456169 http://dx.doi.org/10.1111/j.1742-1241.2009.02227.x |
work_keys_str_mv | AT pratosdel tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement AT lasallej tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement AT matthaeis tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement AT baileycj tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement |